Scilex Holding Company Announces Collaboration to Leverage ACEA Therapeutics’ R&D Expertise and Local Market Connections to Support the Expansion of ZTlido Program in ex-US and Potentially Provide Additional Access to Patients in Certain Key Markets in Fa - Seite 2

“Based on current market demand for Scilex’s innovative non-opioid pain management products, we believe there is a significant commercial opportunity for ZTlido across Greater China markets. We are excited to be in a position with our potential partners to expand access to ZTlido and other important pain solutions with Scilex in the future,” said Xiao Xu, CEO of ACEA.

“This joint collaboration effort with ACEA reflects on our mission to bring our innovative non-opioid medicines to acute and chronic pain patients in greater China region. This agreement is an important step toward our shared goal of bringing safe and effective pain management to people worldwide, to ensure more patients are able to benefit from these innovative medicines,” said Jaisim Shah, Chief Executive Officer and President of Scilex.

For more information on Scilex Holding Company, refer to www.scilexholding.com

For more information on ZTlido including Full Prescribing Information, refer to www.ztlido.com.

For more information on ELYXYB, including Full Prescribing Information, refer to www.elyxyb.com.

For more information on Gloperba, including Full Prescribing Information, refer to www.gloperba.com.

https://www.facebook.com/scilex.pharm

https://www.linkedin.com/company/scilex-holding-company/

[e-mail]

About Scilex Holding Company

Scilex Holding Company is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and is dedicated to advancing and improving patient outcomes. Scilex’s commercial products include: (i) ZTlido (lidocaine topical system) 1.8%, a prescription lidocaine topical product approved by the U.S. Food and Drug Administration (the “FDA”) for the relief of neuropathic pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain; (ii) ELYXYB, a potential first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and (iii) Gloperba, the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.